Vaccine demonstrates benefit in delaying cancer relapse
European Pharmaceutical Review
JANUARY 10, 2024
The AMPLIFY-201 clinical trial evaluating the off-the-shelf cancer vaccine ELI-002 was designed to lower the risk relapse by ‘training’ T cells to recognise KRAS mutations and therefore eliminate KRAS-mutant cells, the team noted. It also showed a favourable safety profile, which is exciting.”
Let's personalize your content